g


Register Interest

Opal Biosciences Ltd

Opal Biosciences Ltd is transforming from a preclinical stage biotechnology company to a revenue-generating pharmaceutical development business through its acquisition and growth of Formulytica Pty Ltd. Formulytica’s formulation manufacturing business to supplies local and overseas companies with clinical and preclinical pharmaceutical materials. The acquisition will complement Opal’s development of novel treatments for antibiotic-resistant or hard-to-treat infections and expand Formulytica’s services.